Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
Biotie Therapies
Biotie Therapies
Activities:
Research & Development
X
LinkedIn
Trending Articles
Innovation in generics: increased efficiency through peptide API synthesis expertise
Leading Swiss pharmaceutical company Bachem explains the benefits of converging LPPS in the manufacturing of gonadotropin-releasing hormone (GnRH) analogues
COVID-19 still a significant risk for the immunocompromised, study finds
AstraZeneca's INFORM study highlights the persistent danger of COVID-19 for the immunocompromised despite the vaccination scheme
US court lifts modified consent decree on Xellia’s Cleveland facility
The Modified Consent Decree imposed on Xellia's Cleveland facility in 2016 has been vacated, receiving a VAI
Lonza's AI-enabled small molecule development tool launches
The company's AI-enabled Route Scouting Service will optimise synthetic route identification when identifying novel APIs
Autoscribe Informatics’ new Australia office supports business growth
The company's move to West Lakes Adelaide expands its ability to service the Asia Pacific region in digitalising laboratory information
Upcoming event
ASGCT Annual Meeting 2024
7-11 May, 2024 | Meeting | Portland, OR
See all
Related Content
Research & Development
Biotie makes changes to management team
Appoints new Chief Executive, Chief Financial Officer and Chief Medical Officer
Finance
Acorda offers US$363m for Biotie Therapeutics
Expanding its pipeline of drugs to treat Parkinson's Disease
Research & Development
Michael J Fox Foundation to finance Parkinson\'s trials for Biotie Therapies and Cynapsus Therapeutics
Biotie will receive US$2m, while Cynapsus grant is $500,000
Finance
Biotie purchases option to acquire Neurelis
Provides opportunity to develop late-stage product for treatment of epileptic seizures
Research & Development
Biotie terminates agreement to buy Newron
Newron is exploring all options for safinamide
Finance
Biotie Therapies to acquire Newron for €45m
Will continue to focus on CNS drug development
Research & Development
Biotie to acquire Synosia in all-share deal
Will create a CNS drug development company
Subscribe now